Cover Image
市場調查報告書

MediPoint:腫瘤搭配診斷檢驗 - 南美市場分析與預測

MediPoint: Companion Diagnostic Tests in Oncology - South America Analysis and Market Forecasts

出版商 GlobalData 商品編碼 303985
出版日期 內容資訊 英文 408 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:腫瘤搭配診斷檢驗 - 南美市場分析與預測 MediPoint: Companion Diagnostic Tests in Oncology - South America Analysis and Market Forecasts
出版日期: 2014年05月21日 內容資訊: 英文 408 Pages
簡介

南美搭配診斷檢查市場因為疾病發生率增加這個主要原因,以巴西為中心,乳癌的HER2檢查已然非常普及,2012年預測將達到1500萬美金的規模。

本報告提供南美市場腫瘤搭配診斷檢查市場的疾病概要及市場結構、彙整目前的未滿足需求、主要市場推動、阻礙要素、今後的市場機會、目前實驗中的主要產品、市場趨勢(過去3年的實績值與今後7年的預測值)、產品部門別的詳細動向、主要企業簡介等調查分析。

第1章 目錄

第2章 簡介

第3章 產業概要

  • 搭配診斷的登場
    • 搭配診斷定義
    • 醫療變化的方面
    • 個體化搭配診斷定義
  • 對疾病的適用
    • 乳癌
    • 大腸癌症
    • 黑色素瘤(Melanoma)
    • 非小細胞肺癌
  • 搭配診斷技術
    • 免疫化學的手法
    • 核酸檢驗
    • 新的手法
  • 搭配診斷的發達
    • 搭配診斷的經濟價值
    • 搭配診斷檢驗的發展時期
    • 策略
    • 合作夥伴的選擇
    • 生物標記的發現
  • 臨床結果
    • 疾病治療的搭配診斷所扮演的角色
    • 搭配診斷檢驗的適用
  • 檢驗趨勢
    • 巴西
  • 市場進入
    • 巴西
  • 法規上的課題與回收(5件)
  • 搭配診斷檢驗上的醫療費給付
    • 南美
  • 企業合併·收購(M&A)/主要的夥伴關係
  • 經濟上的影響
    • 搭配診斷的成本效率性(來自整體及醫療機關的觀點)
  • 推動市場要素
    • 醫療方面的壓力增加
    • 經濟方面的負面壓力
    • 新技術的可用性
    • FDA(美國食品藥物管理局)的法規改革
    • 改善醫藥品開發過程的需求
    • 癌症患病人數的增加
    • 標靶治療的需求擴大
  • 市場阻礙因素
    • 醫療費給付的困難
    • 適應症的消失
    • 生技仿製藥療法的出現
    • 與LDT(研究室所開發的檢查法)的競爭
    • 下一代型遺傳基因定序的登場
    • 選擇設備時研究室的選擇過少
    • 患者對搭配診斷的認知度低
    • 醫生對新搭配診斷檢查的阻力

第4章 競爭力的評估

  • 概要
  • 現在已上市的產品所使用的手法
    • 免疫疾病組織化學
    • 螢光原位雜合系統
    • 聚合酵素鏈鎖反應
  • 競爭力分析
    • 乳癌搭配診斷檢驗
    • 大腸癌症搭配診斷檢驗
    • 黑色素瘤搭配診斷檢驗
    • 非小細胞肺癌搭配診斷檢驗

第5章 未滿足需求

  • 改善癌症治療的必要性
  • 客觀檢查的需求
  • 高通量實驗檢查的需求
  • 醫療費給付的確實性
  • 檢驗所需的體內組織數量和種類
  • 檢驗對象為何?
  • 檢驗的正確性
  • 檢驗的複雜化和流程障礙的增加

第6章 開發中產品

  • 概要
  • 各開發階段的開發平台
  • 開發中產品簡介
    • 乳癌搭配診斷檢驗
    • 大腸癌症搭配診斷檢驗
    • 黑色素瘤搭配診斷檢驗
    • 非小細胞肺癌搭配診斷檢驗

第7章 值得注意的臨床實驗

  • 概要
  • 活用結合特定藥物療法的搭配診斷檢查的開發中產品,主要實驗資訊

第8章 現在·未來市場參與企業

  • 企業策略的趨勢
    • 搭配診斷的經營模式
  • 企業簡介
    • 開發搭配診斷檢驗手法的製藥/治療企業
    • 開發(與製藥企業協作)搭配診斷檢驗手法的診斷企業

第9章 市場未來展望

  • 各市場領域
    • 乳癌搭配診斷檢驗
    • 大腸癌症搭配診斷檢驗
    • 黑色素瘤搭配診斷檢驗
    • 非小細胞肺癌搭配診斷檢驗
    • 手法
  • 各地區
    • 概要
    • 巴西
  • 第10章 附錄

圖表一覽

目錄
Product Code: GDME1102CFR

A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked to a disease condition or therapy. This report provides an analysis of the companion diagnostic market for four major cancers in the US, the 5EU (France, Germany, Italy, Spain, and UK), Brazil, and the some of the Asia-Pacific (APAC) regions (Japan, China, and India), and identifies the unmet needs in this companion diagnostics market. This report analyses companion diagnostic tests used in breast, colorectal, melanoma and non-small cell lung cancer. This report also discusses physician attitudes towards current companion diagnostic tests, and the future of companion diagnostic tests. This report focuses on the major test kits that are supplied to pathology laboratories.

GlobalData estimates the companion diagnostic test market in South America, for breast cancer companion diagnostic tests, principally HER2 tests, to have been worth $15.0m in 2012. Breast cancer companion diagnostic testing is expected to increase in Brazil mainlyt as a result of increasing incidence of the diseasde, with only a modest increase in access to testing amongst breast cancer patients.

Scope

  • An overview of companion diagnostic, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized SA companion diagnostic market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for companion diagnostic.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the companion diagnostic sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving the SA companion diagnostic market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in SA companion diagnostic market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in SA companion diagnostic market landscape? Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Industry Overview

  • 3.1. Emergence of Companion Diagnostics
    • 3.1.1. Definition of Companion Diagnostics
    • 3.1.2. Changing Face of Medicine
    • 3.1.3. Definitions of Companion and Personalized Diagnostics
  • 3.2. Disease Applications
    • 3.2.1. Breast Cancer
    • 3.2.2. Colorectal Cancer
    • 3.2.3. Melanoma
    • 3.2.4. Non-Small Cell Lung Cancer
  • 3.3. Companion Diagnostics Technologies
    • 3.3.1. Immunochemical Techniques
    • 3.3.2. Nucleic Acid Testing
    • 3.3.3. Emerging Technologies
  • 3.4. Companion Diagnostics Development
    • 3.4.1. Economic Value of a Companion Diagnostic
    • 3.4.2. When to Develop a Companion Diagnostic Test
    • 3.4.3. Strategy
    • 3.4.4. Selection of Partner
    • 3.4.5. Biomarker Discovery
  • 3.5. Clinical Outcomes
    • 3.5.1. Role of Companion Diagnostics in Disease Treatment
    • 3.5.2. Companion Diagnostic Test Applications
  • 3.6. Testing Trends
    • 3.6.1. Brazil
  • 3.7. Market Access
    • 3.7.1. Brazil
  • 3.8. Regulatory Issues and Recalls
    • 3.8.1. Dako FDA Warning Letter
    • 3.8.2. HercepTest Recall
    • 3.8.3. Cobas KRAS Test Recall
    • 3.8.4. Cobas BRF V600E Test Recall
    • 3.8.5. Leica Bond HER2 IHC System
  • 3.9. Reimbursement of Companion Diagnostic Tests
    • 3.9.1. South America
  • 3.10. M&A, Key Partnerships
    • 3.10.1. Significant Mergers and Acquisitions
    • 3.10.2. Recent Partnerships
  • 3.11. Economic Impact
    • 3.11.1. Cost Effectiveness of Companion Diagnostics
    • 3.11.2. Cost Effectiveness of Companion Diagnostics: Healthcare Provider Perspective
  • 3.12. Market Drivers
    • 3.12.1. Driver: Increasing Healthcare Pressures
    • 3.12.2. Driver: Adverse Economic Pressures
    • 3.12.3. Driver: Availability of New Technologies
    • 3.12.4. Driver: FDA Regulatory Changes
    • 3.12.5. Driver: Need to Improve Drug Development Processes
    • 3.12.6. Driver: Increasing Cancer Incidence
    • 3.12.7. Driver: Accelerating Demand for Targeted Therapies
  • 3.13. Market Barriers
    • 3.13.1. Barrier: Reimbursement Difficulties
    • 3.13.2. Barrier: Loss of Indication
    • 3.13.3. Barrier: Emergence of Biosimilar Therapies
    • 3.13.4. Barrier: Competition with Laboratory-Developed Tests
    • 3.13.5. Barrier: Emergence of Next-Generation Gene Sequencing
    • 3.13.6. Barrier: Lack of Laboratory Choice in Instrument Selection
    • 3.13.7. Barrier: Lack of Patient Awareness about Companion Diagnostic Tests
    • 3.13.8. Barrier: Physician Resistance to New Companion Diagnostic Tests

4. Competitive Assessment

  • 4.1. Overview
  • 4.2. Techniques in Use by Currently Marketed Products
    • 4.2.1. Immunohistochemistry
    • 4.2.2. Fluorescence In Situ Hybridization
    • 4.2.3. Polymerase Chain Reaction
  • 4.3. Competitive Analysis
    • 4.3.1. Breast Cancer Companion Diagnostic Tests
    • 4.3.2. Colorectal Cancer Companion Diagnostic Tests
    • 4.3.3. Melanoma Companion Diagnostic Tests
    • 4.3.4. Non-Small Cell Lung Cancer Companion Diagnostic Tests

5. Unmet Needs

  • 5.1. Need for Improved Cancer Treatments
  • 5.2. Need for Objective Tests
  • 5.3. Need for High-Throughput Tests
  • 5.4. Certainty of Reimbursement
  • 5.5. Amount and Type of Tissue Needed for Test
  • 5.6. Who Should be Tested?
  • 5.7. Test Accuracy
  • 5.8. Increasing Test Complexity and Increased Process Failure

6. Pipeline Products

  • 6.1. Overview
  • 6.2. Pipeline by Phase of Development
  • 6.3. Pipeline Product Profiles
    • 6.3.1. Breast Cancer Companion Diagnostic Tests
    • 6.3.2. Colorectal Cancer Companion Diagnostic Tests
    • 6.3.3. Melanoma Companion Diagnostic Tests
    • 6.3.4. Non-Small Cell Lung Cancer Companion Diagnostic Tests

7. Clinical Trials to Watch

  • 7.1. Overview
  • 7.2. Key Clinical Trials Utilizing Pipeline Companion Diagnostic Tests Linked to Specific Drug Therapies

8. Current and Future Players

  • 8.1. Trends in Corporate Strategy
    • 8.1.1. Companion Diagnostics Business Models
  • 8.2. Company Profiles
    • 8.2.1. Pharmaceutical/Therapy Companies Developing Companion Diagnostic Tests
    • 8.2.2. Diagnostics Companies Developing Companion Diagnostic Tests (in Partnership with Pharmaceutical Companies)

9. Market Outlooks

  • 9.1. By Market Segment
    • 9.1.1. Breast Cancer Companion Diagnostic Tests
    • 9.1.2. Colorectal Cancer Companion Diagnostic Tests
    • 9.1.3. Melanoma Companion Diagnostic Tests
    • 9.1.4. Non-Small Cell Lung Cancer Companion Diagnostic Tests
    • 9.1.5. Technique
  • 9.2. By Geography
    • 9.2.1. Overview
    • 9.2.2. Brazil

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Report Methodology
    • 10.3.1. Coverage
    • 10.3.2. Secondary Research
    • 10.3.3. Forecasting Methodology
  • 10.4. Physicians Included in this Study
  • 10.5. About the Authors
    • 10.5.1. Andrew Thompson, Ph.D., Senior Analyst, In Vitro Diagnostics
    • 10.5.2. Derek Archila, MBA, Lead Analyst, Medical Devices
    • 10.5.3. Bonnie Bain, PhD, Global Head of Healthcare
  • 10.6. Disclaimer

List of Tables

  • Table 1: Possible Companion Diagnostic Test Platforms
  • Table 2: Specific Breast Cancer Types Associated with Inherited Disorders
  • Table 3: Specific Mutations Associated with Non-Small Cell Lung Cancer
  • Table 4: Weaknesses of ELISA Technique
  • Table 5: Key Stages of PCR Gene Test
  • Table 6: Key Principles Guiding Companion Diagnostic Test Development
  • Table 7: Companion Diagnostic Test Development Partner Selection
  • Table 8: Biomarker Discovery
  • Table 9: Disease Diagnosis, Treatment, and Monitoring
  • Table 10: Application of Companion Diagnostic Tests
  • Table 11: Major Biomarkers currently measured in Cancer Companion Diagnostic Tests
  • Table 12: Breast Cancer Companion Diagnostic Testing (HER2) in Brazil, 2011-2020
  • Table 13: Colorectal Cancer Companion Diagnostic (KRAS) Testing in Brazil, 2011-2020
  • Table 14: Melanoma Companion Diagnostic Testing (BRAF) in Brazil, 2011-2020
  • Table 15: NSCLC Companion Diagnostic Testing (EGFR and ALK Mutation) in Brazil, 2011-2020
  • Table 16: Key Mergers and Acquisitions during 2013-2014
  • Table 17: Partnerships during 2013-2014
  • Table 18: Impact of Companion Diagnostics on Cancer Treatment Costs in France
  • Table 19: Effectiveness of Disease Therapies
  • Table 20: HER2 FISH/iQFISH PharmDx Product Profile
  • Table 21: Common Reasons for HER2 FISH Failure
  • Table 22: HER2 FISH PharmDx/HER2 iQFISH PharmDx SWOT Analysis
  • Table 23: HercepTest Product Profile
  • Table 24: HercepTest Scoring Algorithm
  • Table 25: HercepTest SWOT Analysis
  • Table 26: HER2 CISH PharmDx Product Profile
  • Table 27: HER2 CISH PharmDx SWOT Analysis
  • Table 28: SPOT-Light HER2 CISH Kit Product Profile
  • Table 29: SPOT-Light HER2 CISH Kit SWOT Analysis
  • Table 30: Leica Bond Oracle HER2 IHC System Product Profile
  • Table 31: Leica Bond Oracle HER2 IHC System Test Algorithm
  • Table 32: Leica Bond Oracle HER2 IHC System SWOT Analysis
  • Table 33: Biogenex INSITE HER2/Neu Product Profile
  • Table 34: Biogenex INSITE HER2/Neu SWOT Analysis
  • Table 35: Abbott Pathvysion HER-2 DNA Probe Kit Product Profile
  • Table 36: Abbott Pathvysion HER-2 DNA Probe Kit SWOT Analysis
  • Table 37: Ventana INFORM HER2 Dual ISH Assay Product Profile
  • Table 38: Ventana INFORM HER2 Dual ISH Assay SWOT Analysis
  • Table 39: Pathway HER2/Neu IHC Product Profile
  • Table 40: Pathway HER2/Neu IHC SWOT Analysis
  • Table 41: HerMark Product Profile
  • Table 42: HerMark SWOT Analysis
  • Table 43: Therascreen KRAS RGQ Product Profile
  • Table 44: Therascreen KRAS RGQ SWOT Analysis
  • Table 45: Cobas KRAS Mutation Test Product Profile
  • Table 46: Cobas KRAS Mutation Test SWOT Analysis
  • Table 47: EGFR PharmDx Kit Product Profile
  • Table 48: EGFR PharmDx Kit SWOT Analysis
  • Table 49: THxID BRAF Product Profile
  • Table 50: Effect of Melanin on the THxID BRAF PCR Test
  • Table 51: THxID BRAF SWOT Analysis
  • Table 52: Cobas 4800 BRAF V600 Mutation Test - Melanoma Product Profile
  • Table 53: Interpretation of Cobas BRAF V600 Mutation Test - Melanoma
  • Table 54: Cobas 4800 BRAF V600 Mutation Test - Melanoma SWOT Analysis
  • Table 55: Vysis ALK Break Apart FISH Probe Kit Product Profile
  • Table 56: Abbott Vysis ALK Break Apart FISH Probe Kit SWOT Analysis
  • Table 57: Amoy-Dx EML4-ALK Fusion Gene Detection Kit Product Profile
  • Table 58: Amoy-Dx EML4-ALK Fusion Gene Detection Kit SWOT Analysis
  • Table 59: Therascreen EGFR RGQ PCR Kit Product Profile
  • Table 60: Therascreen EGFR RGQ PCR Kit SWOT Analysis
  • Table 61: ALK IHC Test Product Profile
  • Table 62: ALK IHC Test SWOT Analysis
  • Table 63: Cobas EGFR Mutation Test Product Profile
  • Table 64: Cobas EGFR Mutation Test SWOT Analysis
  • Table 65: Companion Diagnostic Tests Pipeline, 2014
  • Table 66: Neuvax Companion Diagnostic Assay Product Profile
  • Table 67: Neuvax Companion Diagnostic Assay Product SWOT Analysis
  • Table 68: Companion Diagnostic Test - Palbociclib Product Profile
  • Table 69: Companion Diagnostic Test - Palbociclib SWOT Analysis
  • Table 70: Companion Diagnostic Test - Breast Cancer Product Profile
  • Table 71: Companion Diagnostic Test - Breast Cancer SWOT Analysis
  • Table 72: Onapristone Companion Diagnostic Assay Product Profile
  • Table 73: Onapristone Companion Diagnostic Assay SWOT Analysis
  • Table 74: Aromatase Inhibitor Biomarker - Companion Diagnostic Test Product Profile
  • Table 75: Aromatase Inhibitor Biomarker - Companion Diagnostic Test SWOT Analysis
  • Table 76: BRAF Companion Diagnostic Assay - Colon Cancer Product Profile
  • Table 77: BRAF Companion Diagnostic Assay - Colon Cancer SWOT Analysis
  • Table 78: KRAS Companion Diagnostic Assay - Colon Cancer Product Profile
  • Table 79: KRAS Companion Diagnostic Assay - Colon Cancer SWOT Analysis
  • Table 80: PIK3CA Companion Diagnostic Assay - Colorectal Cancer Product Profile
  • Table 81: PIK3CA Companion Diagnostic Assay - Colorectal Cancer SWOT Analysis
  • Table 82: Vectibix Companion Diagnostic Product Profile
  • Table 83: Vectibix Companion Diagnostic SWOT Analysis
  • Table 84: MAGE-A3 Companion Skin Cancer Assay Product Profile
  • Table 85: MAGE-A3 Companion Skin Cancer Assay SWOT Analysis
  • Table 86: GNAQ/GNA11 Companion Diagnostic Assays - Melanoma Product Profile
  • Table 87: GNAQ/GNA11 Companion Diagnostic Assays - Melanoma SWOT Analysis
  • Table 88: Companion Diagnostic Test - Melanoma Cancer Product Profile
  • Table 89: Companion Diagnostic Test - Melanoma Cancer SWOT Analysis
  • Table 90: KRAS Companion Diagnostic Assay - Melanoma Product Profile
  • Table 91: KRAS Companion Diagnostic Assay - Melanoma SWOT Analysis
  • Table 92: Companion Diagnostic Test - Melanoma Product Profile
  • Table 93: Companion Diagnostic Test - Melanoma SWOT Analysis
  • Table 94: BRAF Companion Diagnostic Assay - Lung Cancer Product Profile
  • Table 95: BRAF Companion Diagnostic Assay - Lung Cancer SWOT Analysis
  • Table 96: KRAS Companion Diagnostic Assay - Lung Cancer Product Profile
  • Table 97: KRAS Companion Diagnostic Assay - Lung Cancer SWOT Analysis
  • Table 98: MET Companion Diagnostic Assay - Lung Cancer Product Profile
  • Table 99: MET Companion Diagnostic Assay - Lung Cancer SWOT Analysis
  • Table 100: PIK3CA Companion Diagnostic Assay - Lung Cancer Product Profile
  • Table 101: PIK3CA Companion Diagnostic Assay - Lung Cancer SWOT Analysis
  • Table 102: Companion Diagnostic Device - Lung Cancer Product Profile
  • Table 103: Companion Diagnostic Device - Lung Cancer SWOT Analysis
  • Table 104: Companion Diagnostic Test - Crizotinib Product Profile
  • Table 105: Companion Diagnostic Test - Crizotinib SWOT Analysis
  • Table 106: Companion Diagnostic Test - Dacomitinib Product Profile
  • Table 107: Companion Diagnostic Test - Dacomitinib SWOT Analysis
  • Table 108: T790M Mutation Companion Diagnostic Test Product Profile
  • Table 109: T790M Mutation Companion Diagnostic Test SWOT Analysis
  • Table 110: Entinostat Companion Diagnostic Assay Product Profile
  • Table 111: Entinostat Companion Diagnostic Assay SWOT Analysis
  • Table 112: MUC1 Expression Companion Diagnostic Test Product Profile
  • Table 113: MUC1 Expression Companion Diagnostic Test SWOT Analysis
  • Table 114: Companion Diagnostic Assay - NSCLC Product Profile
  • Table 115: Companion Diagnostic Assay - NSCLC SWOT Analysis
  • Table 116: Key Clinical Trials Utilizing Pipeline Companion Diagnostic Tests Linked to Specific Drug Therapies.
  • Table 117: Company Profile - Amgen
  • Table 118: Amgen's Key Products
  • Table 119: Selected Amgen Anti-Cancer Therapies Currently in Clinical Trials
  • Table 120: Amgen SWOT Analysis
  • Table 121: Company Profile - Arno Therapeutics
  • Table 122: Selected Arno Therapeutics Anti-Cancer Therapies Currently in Clinical Trials
  • Table 123: Arno Therapeutics SWOT Analysis
  • Table 124: Company Profile - AstraZeneca
  • Table 125: Key Events in the Development of AstraZeneca's Drug Portfolio Since 2011
  • Table 126: Key Project Terminations by AstraZeneca Since 2008
  • Table 127: AstraZeneca SWOT Analysis
  • Table 128: Company Profile - Bristol-Myers Squibb
  • Table 129: Recent Key Product Approvals from Bristol-Myers Squibb
  • Table 130: Recent Key BMS Partnerships and Agreements
  • Table 131: Bristol-Myers Squibb SWOT Analysis
  • Table 132: Company Profile - Clovis Oncology
  • Table 133: Clovis Oncology's Key Products
  • Table 134: Clovis Oncology SWOT Analysis
  • Table 135: Company Profile - Eli Lilly and Company
  • Table 136: Eli Lilly and Company SWOT Analysis
  • Table 137: Company Profile - Genentech
  • Table 138: Selected Genentech Marketed Products
  • Table 139: Genentech SWOT Analysis
  • Table 140: Company Profile - Pfizer
  • Table 141: Pfizer SWOT Analysis
  • Table 142: Company Profile - Syndax Pharmaceuticals
  • Table 143: Syndax Pharmaceuticals SWOT Analysis
  • Table 144: Company Profile - Abbott Laboratories
  • Table 145: Abbott's Key Product Areas
  • Table 146: Abbott Laboratories SWOT Analysis, 2013
  • Table 147: Company Profile - Amoy Diagnostics
  • Table 148: Amoy Diagnostics SWOT Analysis, 2013
  • Table 149: Company Profile - Biogenex Laboratories
  • Table 150: Biogenex Laboratories SWOT Analysis, 2013
  • Table 151: Company Profile - BioMerieux
  • Table 152: BioMerieux SWOT Analysis, 2013
  • Table 153: Company Profile - Dako (Agilent Technologies)
  • Table 154: Dako/Agilent Technologies SWOT Analysis
  • Table 155: Company Profile - Illumina
  • Table 156: Illumina Product Areas
  • Table 157: Illumina SWOT Analysis
  • Table 158: Company Profile - Leica Biosystems (Danaher)
  • Table 159: Leica Biosystems/Danaher SWOT Analysis
  • Table 160: Company Profile - Life Technologies (Thermo Fisher Scientific)
  • Table 161: Life Technologies SWOT Analysis
  • Table 162: Company Profile - MolecularMD
  • Table 163: MolecularMD SWOT Analysis
  • Table 164: Company Profile - Myriad Genetics
  • Table 165: Myriad Genetics Major Product Areas
  • Table 166: Myriad Genetics SWOT Analysis
  • Table 167: Company Profile - Qiagen
  • Table 168: Qiagen Major Product Areas
  • Table 169: Qiagen SWOT Analysis
  • Table 170: Company Profile - Roche Diagnostics
  • Table 171: Roche SWOT Analysis
  • Table 172: Company Profile - Siemens Healthcare
  • Table 173: Siemens Healthcare SWOT Analysis
  • Table 174: Company Profile - Ventana Medical Systems
  • Table 175: Ventana Medical Systems SWOT Analysis
  • Table 176: South America Sales Forecast for Breast Cancer Companion Diagnostic Tests ($m), 2011-2020
  • Table 177: South America Sales Forecast for Colorectal Cancer Companion Diagnostic Tests ($m), 2011-2020
  • Table 178: South America Sales Forecast for Melanoma Companion Diagnostic Tests ($m), 2011-2020
  • Table 179: South America Sales Forecast for NSCLC Companion Diagnostic Tests ($m), 2011-2020
  • Table 180: South America Sales Forecast for IHC and Molecular Tests ($m), 2011-2020
  • Table 181: Major Events Affecting the Companion Diagnostic Test Market
  • Table 182: Sales Forecast for Companion Diagnostic Tests ($m) in Brazil, 2011-2020

List of Figures

  • Figure 1: Genomic Sequencing Costs, 2001-2012
  • Figure 2: Use of Proteomics in Personalized Medicine
  • Figure 3: Incidence of Inherited Breast Cancer Mutations among Diagnosed Breast Cancer Patients
  • Figure 4: Basic FISH Process
  • Figure 5: Basic PCR Process
  • Figure 6: Impact of Sample Storage on PCR Outcome
  • Figure 7: Genomic Sequencing Costs, 2001-2012
  • Figure 8: Scientific and Economic Potential of Companion Diagnostics
  • Figure 9: Drug and Diagnostic Test Co-Development
  • Figure 10: Roche Lifecycle Algorithm for Co-Development of a Predictive Diagnostic
  • Figure 11: Key Development Drivers for Companion Diagnostic Tests
  • Figure 12: Qiagen Model to Build a JAK2 Companion Diagnostic Tests Business
  • Figure 13: Breast Cancer Companion Diagnostic Testing (HER2) in Brazil, 2011-2020
  • Figure 14: Colorectal Cancer Companion Diagnostic (KRAS) Testing in Brazil, 2011-2020
  • Figure 15: Melanoma Companion Diagnostic Testing (BRAF) in Brazil, 2011-2020
  • Figure 16: NSCLC Companion Diagnostic Testing (EGFR and ALK Mutation) in Brazil, 2011-2020
  • Figure 17: Multiple Partnerships in Companion Diagnostics during 2013-2014
  • Figure 18: Building a Companion Diagnostics Business: Forming Multiple Partnerships
  • Figure 19: Increasing Medicare Cost of Treatment
  • Figure 20: Growth of Drug Therapy Expenditure in France, 2004-2009
  • Figure 21: Share of Targeted Therapies of Anti-Cancer Drug Costs in France
  • Figure 22: Increase in Approvals of Biologic (Targeted) Therapies
  • Figure 23: EGFR PharmDx Test Adoption Curve
  • Figure 24: Probe Arrangement in the Vysis ALK Break Apart FISH Probe Kit
  • Figure 25: Scorpion Primers
  • Figure 26: Increase in High- and Moderate-Complexity Molecular Tests
  • Figure 27: Reasons for Companion Diagnostic Test Failure
  • Figure 28: Female Breast Cancer Treatment Patterns by Stage, 2008
  • Figure 29: Colon Cancer Treatment Patterns by Stage, 2008
  • Figure 30: Lung Cancer Treatment Patterns by Stage, 2008
  • Figure 31: Expected Companion Diagnostic Test Pipeline, US Approvals, 2014-2019
  • Figure 32: Sponsors of Clinical Trials for Targeted Cancer Therapies
  • Figure 33: Sponsors of Clinical Trials for Targeted Cancer Therapies Based on Mutational Status
  • Figure 34: Sponsors of Clinical Trials for Targeted Cancer Therapies, by Phase
  • Figure 35: South Amercia Sales Forecast for Breast Cancer Companion Diagnostic Tests ($m), 2011-2020
  • Figure 36: South America Sales Forecast for Colorectal Cancer Companion Diagnostic Tests ($m), 2011-2020
  • Figure 37: South America Sales Forecast for Melanoma Companion Diagnostic Tests ($m), 2011-2020
  • Figure 38: South America Sales Forecast for NSCLC Companion Diagnostic Tests ($m), 2011-2020
  • Figure 39: South America Sales Forecast for IHC and Molecular Tests ($m), 2011-2020
  • Figure 40: South America Market Share of Molecular Tests and Immunohistochemistry Tests in 2012 and 2020
  • Figure 41: Sales Forecast for Companion Diagnostic Tests ($m) in Brazil, 2011-2020
Back to Top